Search

everythinglearnresearchcommunity

for

Search:↓

AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.

The user noticed hair thinning since age 15, initially attributed to a Vitamin D deficiency. They are currently using Rogaine and considering Propecia but are hesitant about a scalp biopsy; they seek financially practical treatments for male-pattern baldness.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.

Hair loss, which is sometimes accompanied by itching. Treatments discussed include Minoxidil, finasteride, RU58841 and ketocazole shampoo.

The user started using finasteride, minoxidil, and biotin for hair loss and believes they are a hyper responder, noticing significant changes in hair thickness. They regret not starting earlier and mention using oral minoxidil.

The user is experiencing hair thinning and has a vitamin D deficiency, which they suspect might be causing the issue, but they are also considering androgenic alopecia (AGA) as a cause. They are currently using minoxidil and are unable to get finasteride prescribed, while others suggest addressing the vitamin D deficiency and consulting a dermatologist.

The user is using finasteride, RU58841, and various natural supplements and treatments like seamoss, fish oil, and black rice water spray to combat hair loss, avoiding minoxidil due to dependency concerns. They report thicker hair and regained confidence, while discussing the potential risks and benefits of RU58841 with others.

The conversation is about the role of vitamin deficiencies in hair loss and the effectiveness of treatments like Minoxidil, finasteride, and RU58841. It concludes that while vitamins and nutrition are important, they are not the primary solution for androgenic alopecia.

The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.

A new study that found a single chemical could potentially be responsible for hair loss, and the potential to use this discovery to stimulate hair growth. The conversation also includes various treatments such as Minoxidil, Finasteride, RU58841, microneedling, DUT, and Botox for hair loss.

The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.

A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

The conversation discusses using finasteride or dutasteride to reduce DHT, CosmeRNA to target androgen receptors, and Minoxidil as a vasodilator for hair growth. The regimen aims to maintain hair by addressing DHT-AR ratio and continuous Minoxidil use.

Hair loss treatments, specifically minoxidil (Minoxidil) and finasteride (Fin). The conversation includes comments about non-responders, the possibility of becoming a responder with grapefruit juice, disappointment, and acceptance of baldness.

An SSRI (paroxetine) reduced hair loss and itching for a user with male-pattern baldness, but liver issues forced discontinuation, leading to increased hair loss and anxiety. The user plans to try other anti-anxiety medications, noting stress and anxiety significantly impact hair loss.

A potential treatment for alopecia involving a protein that calms hair follicles has shown promise in rats, but skepticism remains about its applicability to humans. Many users express doubt about the timeline for effective hair loss treatments, comparing it to past unfulfilled promises.

New hair loss treatments like stem cells, hair cloning, and gt20029 are unlikely to be available in the next 5-10 years, with some trials possibly starting by 2026. Current treatments like Minoxidil and Finasteride have been used for decades, and new developments depend on funding and successful trials.

A user is considering a hair loss treatment lotion containing minoxidil, adenosine, caffeine, melatonin, and azelaic acid, questioning the interaction between caffeine and adenosine receptors. Another user suggests adding a topical anti-DHT ingredient like spironolactone, noting it should not be taken orally by men.

Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.

Hair loss is linked to the loss of stem cells in hair follicles, and potential treatments include gene editing and microneedling. Discussions also mention using Minoxidil, finasteride, and dermarolling to improve hair growth.

A 43-year-old noticed significant hair thinning and is using topical minoxidil, dermarolling, Alpecin, biotin, zinc, copper, vitamin D, and rosemary oil. They plan to see an endocrinologist and have blood tests scheduled to investigate further.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

Some embrace baldness, while others promote treatments like minoxidil and finasteride. Opinions differ on accepting baldness versus pursuing hair regrowth.

Diffuse thinners often experience more hair regrowth with DHT blockers like finasteride, possibly due to less DHT sensitivity and the presence of miniaturized, not completely bald, follicles. However, regrowth varies widely among individuals, influenced by factors like genetics, the stage of hair loss, and treatment methods such as minoxidil, microneedling, and dermarolling.

The user has been using a hair loss treatment including oral Minoxidil, topical Minoxidil with Tretinoin and Finasteride, and is considering adding Dutasteride but is concerned about the potential side effects and risks regarding fertility. A reply suggests that having children while on these medications should be fine, advising to avoid letting the partner come into contact with the drugs.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.